Metabolic bone disease
Drug research and approvals for metabolic bone disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 281 studies of metabolic bone disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 281
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment…NCT07920484 · Not reported · Amber Implants B.V. · starts Oct 4, 2026
- Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi AnemiaNCT07901959 · Phase 1 · Rockefeller University · starts Oct 14, 2026
- Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National…NCT07877727 · Not reported · Istituto Giannina Gaslini · starts May 29, 2025
- Effects of Sensorimotor Balance Training vs Digitally Augmented Core Stabilization in Women With OsteoporosisNCT07875894 · Not applicable · Riphah International University · starts Oct 19, 2026
- German Hypoparathyroidism RegistryNCT07857460 · Not reported · University Hospital Augsburg · starts Jul 6, 2021
- Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing…NCT07824102 · Not reported · Martin Blomberg Jensen · starts Jan 1, 2026
- Systemic Biochemical Signature and Functional Quality Index of Calcaneal Bone Marrow Aspirate in Adults Undergoing Foot…NCT07802106 · Not reported · Universidade Sao Francisco · starts Oct 21, 2026
- Dietary Supplements and Middle Aged Women (Collagen & Omega)NCT07740967 · Not applicable · Loughborough University · starts May 1, 2026
Approved 1
- Alendronic acidFarnesyl diphosphate synthase inhibitor
Phase 3 12
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- Risedronic acidFarnesyl diphosphate synthase inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- NitroglycerinSoluble guanylate cyclase activator
- ProgesteroneProgesterone receptor agonist
- RaloxifeneEstrogen receptor beta modulator
- Estrogens, conjugatedEstrogen receptor agonist
- CholecalciferolVitamin D receptor agonist
- Ethinyl estradiolEstrogen receptor alpha agonist
- LevonorgestrelProgesterone receptor agonist
- Ibandronic acidFarnesyl diphosphate synthase inhibitor
- Calcium carbonate
Phase 2 1
- Calcitonin salmonCalcitonin receptor agonist
Phase 1 or earlier 6
- RomosozumabSclerostin inhibitor
- AMG-167Sclerostin inhibitor
- SemaglutideGlucagon-like peptide 1 receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- ErgocalciferolVitamin D receptor agonist
- MelatoninMelatonin receptor agonist
How its trials ended
405 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 78 whose ending is known, 73% met their primary endpoint, 4% missed it and 23% stopped early.
- Completed, result not reported20450%
- Ongoing6616%
- Met its primary endpoint5714%
- Status unknown5714%
- Stopped: other or unclear92%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint31%
- Stopped: funding1<1%
| May 2, 1991 | Etidronate disodiumTreatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral… | MGI Pharma, Inc. | Designated |
| May 2, 1991 | Etidronate disodiumPrevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral… | MGI Pharma, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA